Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 633

1.

Identification of drug-specific public TCR driving severe cutaneous adverse reactions.

Pan RY, Chu MT, Wang CW, Lee YS, Lemonnier F, Michels AW, Schutte R, Ostrov DA, Chen CB, Phillips EJ, Mallal SA, Mockenhaupt M, Bellón T, Tassaneeyakul W, White KD, Roujeau JC, Chung WH, Hung SI.

Nat Commun. 2019 Aug 8;10(1):3569. doi: 10.1038/s41467-019-11396-2.

2.

HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans.

Mockenhaupt M, Wang CW, Hung SI, Sekula P, Schmidt AH, Pan RY, Chen CB, Dunant A, Gouvello SL, Schumacher M, Valeyrie-Allanore L, Bellon T, Kardaun SH, Jan YS, Chung WH, Roujeau JC; RegiSCAR group.

Allergy. 2019 Nov;74(11):2227-2230. doi: 10.1111/all.13821. Epub 2019 May 28. No abstract available.

PMID:
30972788
3.

Controversies in drug allergy: Testing for delayed reactions.

Phillips EJ, Bigliardi P, Bircher AJ, Broyles A, Chang YS, Chung WH, Lehloenya R, Mockenhaupt M, Peter J, Pirmohamed M, Roujeau JC, Shear NH, Tanno LK, Trubiano J, Valluzzi R, Barbaud A.

J Allergy Clin Immunol. 2019 Jan;143(1):66-73. doi: 10.1016/j.jaci.2018.10.030. Epub 2018 Dec 17. Review.

4.

Epidermal Necrolysis, Ocular Complications, and "Cold Medicines".

Roujeau JC, Dunant A, Mockenhaupt M.

J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):703-704. doi: 10.1016/j.jaip.2017.10.033. No abstract available.

PMID:
29525000
5.

SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH 4th, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MD, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ.

J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):38-69. doi: 10.1016/j.jaip.2017.11.023. Review.

6.

[DRESS and viruses: The way forward].

Barbaud A, Dupin N, Roujeau JC.

Ann Dermatol Venereol. 2018 Feb;145(2):128. doi: 10.1016/j.annder.2017.11.011. Epub 2017 Dec 13. French. No abstract available.

PMID:
29248189
7.

New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.

Roujeau JC, Mockenhaupt M, Guillaume JC, Revuz J.

J Invest Dermatol. 2017 Oct;137(10):2047-2049. doi: 10.1016/j.jid.2017.07.828. Review.

8.

[DRESS and viruses].

Barbaud A, Dupin N, Roujeau JC.

Ann Dermatol Venereol. 2018 Feb;145(2):120-124. doi: 10.1016/j.annder.2017.07.003. Epub 2017 Sep 12. Review. French. No abstract available.

PMID:
28911824
9.

[Another 'last word' on Rowell's syndrome].

Roujeau JC, Revuz J.

Ann Dermatol Venereol. 2017 Aug - Sep;144(8-9):e1-e3. doi: 10.1016/j.annder.2017.05.001. Epub 2017 Jul 5. French. No abstract available.

PMID:
28688528
10.

Virus Reactivation in Drug Reaction with Eosinophilia and Systemic Symptoms (Dress) Results from a Strong Drug-Specific Immune Response.

Roujeau JC, Dupin N.

J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):811-812. doi: 10.1016/j.jaip.2016.11.027. No abstract available.

PMID:
28483323
11.

[Another 'last word' on Rowell's syndrome].

Roujeau JC, Revuz J.

Ann Dermatol Venereol. 2017 Apr;144(4):247-249. doi: 10.1016/j.annder.2017.03.001. French. No abstract available. Erratum in: Ann Dermatol Venereol. 2017 Aug - Sep;144(8-9):487.

PMID:
28347405
12.

Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH.

J Invest Dermatol. 2017 May;137(5):1065-1073. doi: 10.1016/j.jid.2016.11.034. Epub 2016 Dec 21.

13.

Re-evaluation of 'drug-induced' erythema multiforme in the medical literature.

Roujeau JC.

Br J Dermatol. 2016 Sep;175(3):650-1. doi: 10.1111/bjd.14841. Epub 2016 Aug 3. No abstract available.

PMID:
27373787
14.

Epidermal necrolysis: 60 years of errors and advances.

Heng YK, Lee HY, Roujeau JC.

Br J Dermatol. 2015 Nov;173(5):1250-4. doi: 10.1111/bjd.13989. Review.

PMID:
26769645
15.

Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.

Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P.

Joint Bone Spine. 2016 May;83(3):314-7. doi: 10.1016/j.jbspin.2015.07.011. Epub 2015 Dec 18.

PMID:
26709250
16.

Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.

Wheatley LM, Plaut M, Schwaninger JM, Banerji A, Castells M, Finkelman FD, Gleich GJ, Guttman-Yassky E, Mallal SA, Naisbitt DJ, Ostrov DA, Phillips EJ, Pichler WJ, Platts-Mills TA, Roujeau JC, Schwartz LB, Trepanier LA.

J Allergy Clin Immunol. 2015 Aug;136(2):262-71.e2. doi: 10.1016/j.jaci.2015.05.027.

17.

Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study.

Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, Wechsler J, de Feraudy S, Duong TA, Delfau-Larue MH, Chosidow O, Wolkenstein P, Roujeau JC.

Br J Dermatol. 2015 Jul;173(1):50-8. doi: 10.1111/bjd.13683. Epub 2015 Apr 16.

PMID:
25630796
18.

Therapeutic management of DRESS: a retrospective study of 38 cases.

Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, Chosidow O, Valeyrie-Allanore L.

J Am Acad Dermatol. 2015 Feb;72(2):246-52. doi: 10.1016/j.jaad.2014.10.032.

PMID:
25592341
19.

Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission.

Duong TA, de Prost N, Ingen-Housz-Oro S, Carrié AS, Zerah F, Valeyrie-Allanore L, Bagot M, Chosidow O, Roujeau JC, Wolkenstein P, Maitre B.

Br J Dermatol. 2015 Feb;172(2):400-5. doi: 10.1111/bjd.13505. Epub 2014 Dec 11.

PMID:
25496398
20.

Comments on: DRESS syndrome.

Kardaun SH, Mockenhaupt M, Roujeau JC.

J Am Acad Dermatol. 2014 Nov;71(5):1000-1000.e2. doi: 10.1016/j.jaad.2013.11.053. Epub 2014 Oct 15. No abstract available.

PMID:
25437959
21.

Management of nonimmediate hypersensitivity reactions to drugs.

Roujeau JC, Haddad C, Paulmann M, Mockenhaupt M.

Immunol Allergy Clin North Am. 2014 Aug;34(3):473-87, vii. doi: 10.1016/j.iac.2014.04.012. Review.

PMID:
25017673
22.

HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.

Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, Tsai SH, Wu TL, Bellón T, Tamouza R, Fortier C, Toubert A, Charron D, Hovnanian A, Wolkenstein P, Chung WH, Mockenhaupt M, Roujeau JC.

Pharmacogenomics J. 2014 Jun;14(3):281-8. doi: 10.1038/tpj.2013.40. Epub 2013 Dec 10.

PMID:
24322785
23.

Impact of STROBE statement publication on quality of observational study reporting: interrupted time series versus before-after analysis.

Bastuji-Garin S, Sbidian E, Gaudy-Marqueste C, Ferrat E, Roujeau JC, Richard MA, Canoui-Poitrine F; European Dermatology Network (EDEN).

PLoS One. 2013 Aug 26;8(8):e64733. doi: 10.1371/journal.pone.0064733. eCollection 2013.

24.

Generalized pustular eruptions: time to adapt the disease taxonomy to the genetic architecture?

Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, Roujeau JC, Sekula P, Simpson MA, Trembath RC, Mockenhaupt M, Smith CH.

J Invest Dermatol. 2014 Feb;134(2):580-581. doi: 10.1038/jid.2013.349. Epub 2013 Aug 16. No abstract available.

25.

Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients.

Hotz C, Valeyrie-Allanore L, Haddad C, Bouvresse S, Ortonne N, Duong TA, Ingen-Housz-Oro S, Roujeau JC, Wolkenstein P, Chosidow O.

Br J Dermatol. 2013 Dec;169(6):1223-32. doi: 10.1111/bjd.12502.

PMID:
23855377
26.

Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.

Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeau JC; RegiSCAR study group.

Br J Dermatol. 2013 Nov;169(5):1071-80. doi: 10.1111/bjd.12501.

PMID:
23855313
27.

Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms.

Chanal J, Ingen-Housz-Oro S, Ortonne N, Duong TA, Thomas M, Valeyrie-Allanore L, Lebrun-Vignes B, André C, Roujeau JC, Chosidow O, Wolkenstein P.

Br J Dermatol. 2013 Nov;169(5):1041-8. doi: 10.1111/bjd.12488.

PMID:
23815152
28.

Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk?

Haddad C, Sidoroff A, Kardaun SH, Mockenhaupt M, Creamer D, Dunant A, Roujeau JC.

Drug Saf. 2013 Aug;36(8):681-6. doi: 10.1007/s40264-013-0070-6.

PMID:
23743691
29.

Lack of a specific humoral autoreactivity in sera from patients with early erythema exsudativum multiforme majus.

Komorowski L, Mockenhaupt M, Sekula P, Roujeau JC, Probst C, Teegen B, Li W, Stöcker W, Zillikens D.

J Invest Dermatol. 2013 Dec;133(12):2799-2802. doi: 10.1038/jid.2013.242. Epub 2013 Jun 6. No abstract available.

30.

Telaprevir-related dermatitis.

Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS.

JAMA Dermatol. 2013 Feb;149(2):152-8.

PMID:
23560295
31.

Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.

Colliou N, Picard D, Caillot F, Calbo S, Le Corre S, Lim A, Lemercier B, Le Mauff B, Maho-Vaillant M, Jacquot S, Bedane C, Bernard P, Caux F, Prost C, Delaporte E, Doutre MS, Dreno B, Franck N, Ingen-Housz-Oro S, Chosidow O, Pauwels C, Picard C, Roujeau JC, Sigal M, Tancrede-Bohin E, Templier I, Eming R, Hertl M, D'Incan M, Joly P, Musette P.

Sci Transl Med. 2013 Mar 6;5(175):175ra30. doi: 10.1126/scitranslmed.3005166.

32.

Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Lipowicz S, Sekula P, Ingen-Housz-Oro S, Liss Y, Sassolas B, Dunant A, Roujeau JC, Mockenhaupt M.

Br J Dermatol. 2013 Apr;168(4):726-32. doi: 10.1111/bjd.12133. Epub 2013 Feb 16.

PMID:
23413807
33.

Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC; RegiSCAR study group.

J Invest Dermatol. 2013 May;133(5):1197-204. doi: 10.1038/jid.2012.510. Epub 2013 Feb 7.

34.

Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis.

Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, Roujeau JC, Sekula P, Simpson MA, Trembath RC, Mockenhaupt M, Smith CH.

J Invest Dermatol. 2013 Jul;133(7):1904-7. doi: 10.1038/jid.2013.44. Epub 2013 Jan 28. No abstract available.

35.

Stevens-Johnson Syndrome and toxic epidermal necrolysis: improving the support to victims.

Roujeau JC.

Drug Saf. 2013 Feb;36(2):145-6. doi: 10.1007/s40264-012-0008-4. No abstract available.

PMID:
23329542
36.

Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?

Bouvresse S, Valeyrie-Allanore L, Ortonne N, Konstantinou MP, Kardaun SH, Bagot M, Wolkenstein P, Roujeau JC.

Orphanet J Rare Dis. 2012 Sep 25;7:72. doi: 10.1186/1750-1172-7-72.

37.

The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.

Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Roujeau JC.

Br J Dermatol. 2012 Sep;167(3):555-62. doi: 10.1111/j.1365-2133.2012.11074.x.

PMID:
22639874
38.

The value of BP230 enzyme-linked immunosorbent assay in the diagnosis and immunological follow-up of bullous pemphigoid.

Le Saché-de Peufeilhoux L, Ingen-Housz-Oro S, Hue S, Sbidian E, Valeyrie-Allanore L, Ortonne N, Roujeau JC, Wolkenstein P, Chosidow O, André C.

Dermatology. 2012;224(2):154-9. doi: 10.1159/000337545. Epub 2012 Apr 18.

PMID:
22516798
39.

Poor benefit/risk balance of intravenous immunoglobulins in DRESS.

Joly P, Janela B, Tetart F, Rogez S, Picard D, D'Incan M, Descamps V, Collet E, Roujeau JC, Musette P.

Arch Dermatol. 2012 Apr;148(4):543-4. doi: 10.1001/archderm.148.4.dlt120002-c. No abstract available.

PMID:
22508885
40.

Grover's disease in a renal transplant patient, after hemodialysis renewal.

Bassi E, Roujeau JC, Grimbert P, Ortonne N, Bagot M.

G Ital Dermatol Venereol. 2012 Apr;147(2):222-3. No abstract available.

PMID:
22481593
41.

[Can drug-induced rashes constitute epidemics?].

Roujeau JC.

Ann Dermatol Venereol. 2012 Jan;139(1):3-5. doi: 10.1016/j.annder.2011.11.001. Epub 2011 Dec 26. French. No abstract available.

PMID:
22225735
42.

Drug-induced epidermal necrolysis: Important new piece to end the puzzle.

Roujeau JC, Bricard G, Nicolas JF.

J Allergy Clin Immunol. 2011 Dec;128(6):1277-8. doi: 10.1016/j.jaci.2011.10.015. No abstract available.

PMID:
22133320
43.

Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis.

Tang YH, Mockenhaupt M, Henry A, Bounoua M, Naldi L, Le Gouvello S, Bensussan A, Roujeau JC.

Clin Exp Allergy. 2012 Feb;42(2):248-54. doi: 10.1111/j.1365-2222.2011.03875.x. Epub 2011 Oct 6.

PMID:
22092454
44.

Prognostic value of histologic features of toxic epidermal necrolysis.

Valeyrie-Allanore L, Bastuji-Garin S, Guégan S, Ortonne N, Bagot M, Roujeau JC, Revuz JE, Wechsler J, Wolkenstein P.

J Am Acad Dermatol. 2013 Feb;68(2):e29-35. doi: 10.1016/j.jaad.2011.10.007. Epub 2011 Nov 16.

PMID:
22088428
45.

[Auto-immune thyroiditis and drug reaction with eosinophilia and systemic symptoms (DRESS) associated with HHV-6 viral reactivation].

Funck-Brentano E, Duong T, Family D, Bouaziz JD, Ortonne N, Bagot M, Roujeau JC, Wolkenstein P, Valeyrie-Allanore L.

Ann Dermatol Venereol. 2011 Aug-Sep;138(8-9):580-5. doi: 10.1016/j.annder.2011.01.048. Epub 2011 Mar 21. French.

PMID:
21893231
46.

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.

Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC.

J Hepatol. 2012 Feb;56(2):455-63. doi: 10.1016/j.jhep.2011.08.006. Epub 2011 Aug 30. Review.

47.

Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe.

Génin E, Schumacher M, Roujeau JC, Naldi L, Liss Y, Kazma R, Sekula P, Hovnanian A, Mockenhaupt M.

Orphanet J Rare Dis. 2011 Jul 29;6:52. doi: 10.1186/1750-1172-6-52.

48.
49.

The DRESS syndrome: a literature review.

Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC.

Am J Med. 2011 Jul;124(7):588-97. doi: 10.1016/j.amjmed.2011.01.017. Epub 2011 May 17. Review.

PMID:
21592453
50.

Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole.

Kelly JP, Kaufman DW, Dunant A, Mockenhaupt M, Roujeau JC.

J Am Acad Dermatol. 2011 Jun;64(6):1193-4. doi: 10.1016/j.jaad.2009.08.036. No abstract available.

PMID:
21571188

Supplemental Content

Loading ...
Support Center